Antenna Group Expands Global Footprint with Acquisition of Czech Republic’s Rubikon PR
4.9.2024 13:00:00 EEST | Business Wire | Press release
Antenna Group announced today the acquisition of Rubikon PR, a leading Czech public relations and marketing firm. This move marks a significant expansion of Antenna Group's European operations and reinforces its commitment to driving positive global change through innovative communication strategies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904319818/en/
(Graphic: Business Wire)
Founded in 2012, Rubikon is known for its expertise in social impact, fintech, real estate, technology, and the industrial sector. By seamlessly integrating Rubikon into its global operations, Antenna is both expanding its global footprint and enhancing its ability to deliver creative, data-driven solutions at scale. This strategic integration will provide Rubikon's impressive client roster - including Too Good To Go, Freedom Finance, and SkyShowtime - with access to Antenna Group’s full-stack digital marketing, communications, and public affairs services, as well as its deep domain expertise, and award-winning creative talent.
The synergy created by this union is particularly timely given the Czech Republic's burgeoning climate tech sector. Consumer-friendly regulations in the Czech Republic have made it easier for homeowners to install rooftop solar, and the utility-scale solar industry is in its early stages of development. With a 236% increase in installed PV capacity in 2023, the Central and Eastern European (CEE) region and the European Union present exciting opportunities for sustainable growth and innovation.
"We are thrilled to welcome Rubikon into the Antenna Group family,” said Keith Zakheim, CEO of Antenna Group, “The acquisition is a significant milestone for Antenna as it further strengthens our ability to partner with global companies that are fostering innovation, driving sustainable growth across the planet and making a meaningful impact at scale. This union is not just an expansion of our geographical footprint; but, it amplifies our ability to craft impactful narratives that resonate across borders. This partnership embodies our commitment to fostering a more sustainable future through the power of storytelling, creativity, and technology. Together, we're poised to break new ground, connecting brands with audiences across borders and driving positive change in an increasingly interconnected world."
Šimon Rákosník, EVP of CEE Region, added, "Joining Antenna Group opens up a world of possibilities for our clients and our team. We're excited to combine our local insights with Antenna’s global expertise, particularly in areas like cleantech and sustainable technologies. Together, we're poised to create communication strategies that drive business success and contribute to solving some of the world's most pressing challenges."
This acquisition, following its recent expansion into London, underscores Antenna Group’s dedication to building a truly global, integrated network that can meet clients' evolving needs in an increasingly complex marketplace. By combining Rubikon's regional expertise with its worldwide resources, Antenna is building a powerhouse capable of delivering unparalleled value and driving positive change across North America, Europe, and beyond.
ABOUT ANTENNA GROUP
Antenna Group is a global integrated marketing and communications agency partnering with the world’s most exciting and disruptive companies across climate, energy, mobility, real estate, healthcare, and emerging B2B tech sectors. Our clients are transformational and distinguished corporations, startups, investors, and nonprofits at the bleeding edge of the Age of Adoption — the world today in which companies representing every economic sector are furiously adopting climate tech and sustainable solutions. To learn more, please visit antennagroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904319818/en/
Contacts
Media:
Isaac Steinmetz
Antenna Group
isaac.steinmetz@antennagroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom